

14 October 2020

ASX ANNOUNCEMENT

Appointment of Non-Executive Director – Gordon Naylor

Medical Developments International Limited (ASX: MVP) is delighted to announce the appointment of Gordon Naylor as a Non-Executive Director of the Company with immediate effect.

Gordon has enjoyed a long and successful international business career. For over 30 years he was a key part of the internationalisation of the CSL Group, a global specialty biotechnology company that was established in Australia and grew to become Australia's largest public company. Gordon held a range of business and functional leadership roles within CSL including Chief Financial Officer. At the time of his retirement from CSL, he was the President of Seqirus where he led the 3-year turnaround of that business into one of the most successful vaccine companies in the world. In 2016 Seqirus was highly unprofitable with a turnover of circa \$700m. By 2019 the business generated circa \$150m EBIT from a turnover of \$1.2b.

Gordon holds a Bachelor of Engineering (Honours), a Graduate Diploma in Computer Science and an MBA as well as being a CPA and a graduate of the Australian Institute of Company Directors.

Chairman of MVP, Mr. David Williams said: *"Gordon has very broad experience, spanning numerous senior operations and corporate roles within CSL, combined with advanced manufacturing success, hands-on international expansion, business acquisition and restructure experience, and will add significant experience and depth to the Board of Directors. We are very grateful to have him as part of the team and especially now when we are targeting further international registrations and growth across the globe."*

Gordon Naylor said *"This is my first board role since retiring from CSL. Before accepting the role, I undertook significant due diligence to be sure I could add value. I was hands-on at CSL and I plan to be an energetic Director at MVP. The prospects are exciting, and I am looking forward to my first Board Meeting this month."*

Mr Williams added *"The fact that Gordon and our new CEO, Brent MacGregor worked closely together at Seqirus is an added benefit of his appointment."* (see separate ASX announcement)

Authorised for release by MVP Company Secretary, Mark Edwards.

Enquiries:

David Williams
Chairman
Medical Developments International Ltd
+61 414 383 593



About Pentrox®

Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox is now approved for sale in more than 40 countries and has been used safely and effectively for more than 40 years in Australia with more than 7.0 million units sold. There is growing interest in Penthrox being used in patients undergoing investigatory procedures, as well as operational procedures such as colonoscopy.

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast-acting trauma and emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.

For personal use only